MARKET

SGMO

SGMO

Sangamo Therapeutics Inc
NASDAQ
0.3869
+0.0081
+2.14%
After Hours: 0.3980 +0.0111 +2.87% 19:58 02/13 EST
OPEN
0.3827
PREV CLOSE
0.3788
HIGH
0.4058
LOW
0.3751
VOLUME
2.58M
TURNOVER
--
52 WEEK HIGH
1.238
52 WEEK LOW
0.3450
MARKET CAP
143.80M
P/E (TTM)
-0.8738
1D
5D
1M
3M
1Y
5Y
1D
WORLD 2026 Data De-Risk Sangamo’s Fabry Gene Therapy, Supporting Accelerated Approval Path and Long-Term Buy Thesis
TipRanks · 4d ago
Weekly Report: what happened at SGMO last week (0202-0206)?
Weekly Report · 5d ago
Sangamo Biosciences launches dilutive February 2026 financing
TipRanks · 02/04 13:59
Sangamo To Present Positive Study Data Of ST-920 In Fabry Disease At WORLD Symposium 2026
NASDAQ · 02/04 08:54
Sangamo advances Fabry gene therapy with pivotal STAAR data
TipRanks · 02/03 21:35
Sangamo Therapeutics Data From Phase 1/2 STAAR Trial Evaluating Isaralgagene Civaparvovec Shows Positive Mean Annualized Estimated Glomerular Filtration Rate Slope At 52 Weeks
Benzinga · 02/03 21:25
Sangamo Therapeutics Announces Positive Phase 1/2 Data for Fabry Disease Gene Therapy Candidate
Reuters · 02/03 21:09
Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor
Reuters · 02/03 21:09
More
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Webull offers Sangamo Therapeutics Inc stock information, including NASDAQ: SGMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMO stock methods without spending real money on the virtual paper trading platform.